Compass Therapeutics and AstraZeneca have both provided updates to their respective clinical therapeutic programs targeting biliary tract cancers.

AstraZeneca shared positive results from the company’s TOPAZ-1 Phase III trial on Imfinzi (durvalumab) in increasing the chances for survival in advanced biliary tract cancer patients when combined with standard-of-care chemotherapy regimens.

Germany-based CellAct struck a deal with the Mundipharma network of independent companies for its anticancer drug agent CAP7.1.